Ophthalmology News and Research

RSS

Ophthalmology is the specialized field of medicine that focuses on the health of the eye. It includes the anatomy, physiology and diseases that may affect the eye. Historically, the science of ophthalmology encompassed all aspects of visual function, both in health and in illness. Additionally, ophthalmology also includes animal eyes as ocular function and optic diseases are similar among humans and animals.

Study explores regular aspirin use and potential risks for macular degeneration

This week, a study published in the journal JAMA Internal Medicine, explored the connection between regular aspirin use and the potential risks for developing the blinding eye disease, macular degeneration. As a result, there is increased confusion and anxiety in the general public about whether aspirin can harm your vision and what to do if you need the heart-protective therapy.

28 Jan 2013

Extramacular scanning shows promise in uveitic disorders

New optical coherence tomography scanning protocols offer enhanced characterization of patients with birdshot chorioretinopathy, UK researchers report.

25 Jan 2013

Neuromuscular blockade (NMB) reversal

General anesthesia is made up of three components: hypnotic medicines, to induce sleep; analgesics, or medicines to inhibit pain; and NMB agents that induce muscle relaxation. Anesthesiology professionals use NMB to relax a patient’s muscles and prevent involuntary movement that could impact surgery.

24 Jan 2013

Gene therapy does not slow or halt progression of cell loss in Leber congenital amaurosis

Independent clinical trials, including one conducted at the Scheie Eye Institute at the Perelman School of Medicine, have reported safety and efficacy for Leber congenital amaurosis (LCA), a congenital form of blindness caused by mutations in a gene (RPE65) required for recycling vitamin A in the retina. Inherited retinal degenerative diseases were previously considered untreatable and incurable.

23 Jan 2013

FDA approves Ampio’s IND for Optina for treatment of diabetic macular edema

Ampio Pharmaceuticals, Inc. announced today that the FDA has accepted the Company's IND for Optina™ for the treatment of diabetic macular edema (DME). Ampio plans to commence enrollment in a clinical trial in the first quarter of 2013. The FDA granted Optina™ 505(b)(2) status in July, 2012. Drugs designated under this pathway can be approved on a single trial.

22 Jan 2013

Gene therapy improves vision but does not halt progression of cell loss

22 Jan 2013

Macular pigment screening: an interview with Jaquie Finn, Product Line Manager at Elektron Technology

AMD is the leading cause of vision loss in anyone over 50 and globally in 2010 it was estimated to cost $340 billion to treat AMD. The costs are set to spiral over the next 20 years and really over burden the healthcare system unless people start to take preventative action.

18 Jan 2013

Study identifies genes for central corneal thickness that may cause eye conditions

Scientists at Singapore Eye Research Institute and A*STAR's Genome Institute of Singapore have succeeded in identifying genes for central corneal thickness that may cause potentially blinding eye conditions. These eye conditions include glaucoma, as well as the progressive thinning of the cornea, which may eventually lead to a need for corneal transplantation.

17 Jan 2013

SF3B1 gene mutations in uveal melanoma linked to favorable features

Melanomas that develop in the eye often are fatal. Now, scientists at Washington University School of Medicine in St. Louis report they have identified a mutated gene in melanoma tumors of the eye that appears to predict a good outcome.

17 Jan 2013

Eyes also need light to develop normally during pregnancy

New research in Nature concludes the eye – which depends on light to see – also needs light to develop normally during pregnancy.

17 Jan 2013

Knee cartilage repair success with new biomaterial

In a small study, researchers reported increased healthy tissue growth after surgical repair of damaged cartilage if they put a “hydrogel” scaffolding into the wound to support and nourish the healing process. The squishy hydrogel material was implanted in 15 patients during standard microfracture surgery, in which tiny holes are punched in a bone near the injured cartilage. The holes stimulate patients’ own specialized stem cells to emerge from bone marrow and grow new cartilage atop the bone.

15 Jan 2013

Iris nevi have ‘low’ malignant potential

The malignant transformation rate for iris nevi is 8% over 15 years, a case series by US researchers has found.

15 Jan 2013

Aggressive surveillance questionable for eye melanoma recurrence

Patients treated for primary choroidal or ciliary body melanoma may not always benefit from an aggressive surveillance strategy for the detection of metastatic disease, caution US researchers.

14 Jan 2013

Dental diversion plan eases burden in busy EDs

Hospital emergency departments may benefit from having a diversion plan in place to deal with dental patients, say US researchers writing in the Journal of Oral and Maxillofacial Surgery.

14 Jan 2013

UCSF teams to study new ways to reduce childhood mortality and disease in developing nations

Two UCSF teams have received a total of $16 million from the Bill & Melinda Gates Foundation to study new ways to significantly reduce childhood mortality and disease in developing nations.

11 Jan 2013

RPB honors Mass. Eye and Ear ophthalmologist with Senior Scientific Investigator Award

Reza Dana, M.D., M.P.H., M.Sc. of Mass. Eye and Ear/Harvard Medical School, was awarded the Research to Prevent Blindness (RPB) Senior Scientific Investigator Award in the amount of $150,000 to support research into the causes, treatment and prevention of blinding diseases.

9 Jan 2013

Risk factors for retinopathy of prematurity identified

Birthweight and gestational age are risk factors for retinopathy of prematurity and should be considered when screening infants for the condition, a study by Turkish researchers shows.

9 Jan 2013

Merck’s resubmission of the NDA for suggammadex sodium injection accepted for review by the FDA

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the resubmission of the New Drug Application (NDA) for sugammadex sodium injection has been accepted for review by the U.S. Food and Drug Administration (FDA). Merck expects the FDA’s review to be completed in the first half of 2013.

7 Jan 2013

Local conjunctival metastases ‘may be under-recognized’

Local conjunctival metastases may represent under-recognized lesions arising from the dissemination of primary conjunctival melanoma via local vessels, suggest findings published in the British Journal of Ophthalmology.

4 Jan 2013

Regenerative medicine: an interview with Christophe Dardel, President of DSM Biomedical

Regenerative medicine is a new, exciting field that is based upon the belief that the human body has the inherent power to heal itself, but in some instances it just needs a little help.

3 Jan 2013